NCT06220214View on ClinicalTrials.gov

Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 6, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

August 31, 2026

Conditions
Breast CancerLocally Advanced Breast CancerNeoadjuvant ChemotherapyHER2-positive Breast CancerTriple Negative Breast CancerTNBC, Triple Negative Breast Cancer
Interventions
DIAGNOSTIC_TEST

CEDM

Contrast Enhanced Digital Mammography

DIAGNOSTIC_TEST

CEDBT

Contrast-Enhanced Digital Breast Tomosynthesis

DRUG

Omnipaque 350mgI/mL Solution for Injection

Injection of an FDA approved iodinated contrast agent is required to undergo the imaging procedures. It is not the intent of the study to evaluate the contrast agent, but it will be administered at the time of experimental imaging.

Trial Locations (1)

11794

RECRUITING

Stony Brook Breast Center, Stony Brook

All Listed Sponsors
lead

Alison Stopeck

OTHER